Site Sponsors
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D
Posted in | Nanomedicine | Nanobusiness

There is 1 related live offer.

Save 25% on magneTherm

Cancer Therapeutics Retains Firm to Manage Company's Communications Program

Published on May 7, 2009 at 1:06 AM

Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments, announced today the company has retained The Cervelle Group, a nationally known investor relations and public relations firm to manage the company's communications program with shareholders and the media. Cancer Therapeutics is compensating The Cervelle Group 75,000 shares of restricted common stock for the three (3) months of service.

The Cervelle Group (www.thecervellegroup.com), based in Orlando, FL, will focus on communicating with shareholders, prospective investors and the media concerning Cancer Therapeutics. They will also assist with the dispensing of information on the Company as well as its growth strategy and broadening the Company's visibility.

"Medicine and treatments for a variety of diseases and ailments are continuing to advance at a record pace, we believe the idea of what Cancer Therapeutics is based on is not only a valid story but is a real company with tremendous potential," said Rob M. Karbowsky, President of the Cervelle Group LLC. "Cervelle specializes in working with undiscovered companies who have solid management, a great story to tell and a significant upside for revenue generation -- CTHP has these characteristics."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit